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Abstract
Objective To compare the predictive power of the main existing and
recently proposed schemes for stratification of risk of stroke in older
patients with atrial fibrillation.
Design Comparative cohort study of eight risk stratification scores.
Setting Trial of thromboprophylaxis in stroke, the Birmingham Atrial
Fibrillation in the Aged (BAFTA) trial.
Participants 665 patients aged 75 or over with atrial fibrillation based
in the community who were randomised to the BAFTA trial and were not
taking warfarin throughout or for part of the study period.
Main outcome measures Events rates of stroke and thromboembolism.
Results 54 (8%) patients had an ischaemic stroke, four (0.6%) had a
systemic embolism, and 13 (2%) had a transient ischaemic attack. The
distribution of patients classified into the three risk categories (low,
moderate, high) was similar across three of the risk stratification scores
(revised CHADS2, NICE, ACC/AHA/ESC), with most patients categorised
as high risk (65-69%, n=460-457) and the remaining classified as
moderate risk. The original CHADS2 (Congestive heart failure,
Hypertension, Age ≥75 years, Diabetes, previous Stroke) score identified
the lowest number as high risk (27%, n=180). The incremental risk scores
of CHADS2, Rietbrock modified CHADS2, and CHA2DS2-VASc
(CHA2DS2-Vascular disease, Age 65-74 years, Sex) failed to show an
increase in risk at the upper range of scores. The predictive accuracy
was similar across the tested schemes with C statistic ranging from 0.55
(original CHADS2) to 0.62 (Rietbrock modified CHADS2), with all except
the original CHADS2 predicting better than chance. Bootstrapped paired
comparisons provided no evidence of significant differences between
the discriminatory ability of the schemes.
Conclusions Based on this single trial population, current risk
stratification schemes in older people with atrial fibrillation have only
limited ability to predict the risk of stroke. Given the systematic
undertreatment of older people with anticoagulation, and the relative
safety of warfarin versus aspirin in those aged over 70, there could be
a pragmatic rationale for classifying all patients over 75 as “high risk”
until better tools are available.
Introduction
Atrial fibrillation is the most common chronic cardiac
arrhythmia and is associated with increased morbidity and
mortality.
1RecentdatafromtheScreeningforAtrialFibrillation
in the Elderly (SAFE) trial showed a prevalence of atrial
fibrillation of 6% in people aged 65-74, 12% in people aged
75-84, and 16% in people aged 85 and over.
2 The main
importance of atrial fibrillation is that it remains a major
independent risk factor for stroke and thromboembolism,
3
particularly in older patients.
A large evidence base supports the efficacy of oral
anticoagulation (with vitamin K antagonists, such as warfarin),
which can reduce the risk of stroke by two thirds.
4 The
alternative of antiplatelet treatment decreases the risk of stroke
by only 22%,
5 a reduction that might merely reflect the known
benefits of aspirin in secondary prevention of cardiovascular
disease. Despite this better efficacy, however, vitamin K
antagonists have been perceived as linked to more adverse
events in older people
6 and are costlier and more complicated
to implement because of the need to monitor the international
normalised ratio (INR), leading to guidelines recommending
the use of stroke risk scores to triage patients to vitamin K
antagonists or aspirin. Even though a new generation of
anticoagulants (oral direct thrombin inhibitors and oral factor
Xa inhibitors), which do not require monitoring, are starting to
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Research
RESEARCHgain market authorisation, their initial high cost will mean they
will not entirely displace vitamin K antagonists or, therefore,
remove the need to stratify risk in patients, especially as the
newagentshavesimilarrisksofbleedstovitaminKantagonists.
Various clinical and investigation features have been
incorporated into several risk stratification schemes, usually
with categories of high, intermediate/moderate, or low risk,
equating to the likely stroke risk by category. For example,
application of the CHADS2 (Congestive heart failure,
Hypertension,Age≥75years,Diabetes,previousStroke)score
in one cohort
7 resulted in an observed annual risk of stroke of
under 2% for those with a score of 0 (defined as low risk),
around 3% for those with a score of 1 (moderate risk), and over
4% for those with a score of 2 (moderate risk in the original
CHADS2score, high risk in the revised CHADS2score), rising
to 13% at score 5 and 18% at score 6. These various scores are
derivedlargelyfromriskfactorsidentifiedfromthenon-vitamin
Kantagonistarmsoftrialcohortsandonehistoricalcohortstudy
(Framingham). Unfortunately, these derivation cohorts show
considerable diversity in the characteristics of the patients
included (table 1) and are therefore not particularly
representative of the general population with atrial fibrillation,
especially in relation to the low proportion of older patients in
the cohorts. Furthermore, the proportion with previous stroke
or transient ischaemic attack is highly variable, from a high of
25% in the cohort first used to test CHADS2,
7 using a sample
from the National Registry of Atrial Fibrillation in the United
States, to a low of 3.3% in the cohort by van Walraven et al.
8
Not surprisingly therefore, existing stroke risk stratification
schemes have widely varying proportions categorised as high,
intermediate, and low risk, and previous studies have shown
generally modest predictive value in predicting stroke and
thromboembolism (C statistics of about 0.6).
9
This poses the question of whether stroke risk scores are
adequate, especially in older people, in whom rates of atrial
fibrillation are the highest (56% of the prevalent population in
the United Kingdom with atrial fibrillation are aged over 75
and 85% over 65
10) and the risks of stroke are the greatest.
Populationsofolderpeoplehavenotbeensystematicallystudied
in previous validation studies of stroke risk scores.
RecentdatafromtheBirminghamAtrialFibrillationTreatment
of the Aged (BAFTA) trial have supported the use of vitamin
K antagonists (to target INR of 2.5) in older people, with a
reductioninmajordisablingstokeof52%comparedwithaspirin
75mgdailyandnodifferenceinmajorbleedingevents.
11Indeed,
the efficacy of aspirin seems to decline beyond the age of 70,
whereastheriskofbleedingincreases.
12Eveninlowriskpatients
with atrial fibrillation, aspirin might be no better than placebo
for reducing thromboembolic events and have more adverse
effects (especially bleeding).
13 Current evidence is therefore
more definitive regarding treatment recommendations: all high
risk patients should be offered a vitamin K antagonist, if it can
be tolerated, as well as most patients at intermediate risk.
Continuedsurveys,however,showthatlessthanhalfofpatients
eligible for warfarin are treated with a vitamin K antagonist,
and rates of underuse are highest in older people.
14 Stroke risk
scores might therefore continue to have a practical role as long
as therapeutic dilemmas remain, but only if they reliably
distinguish between risk groups.
A recent study in the BMJ reported the observed annual rates
of thromboembolic events in a large registry cohort of Danish
patients admitted with atrial fibrillation and compared this to
riskcategorisationestimatedbyCHADS2andCHA2DS2-VASc
(CHA2DS2-Vascular disease, Age 65-74 years, Sex).
15 Oleson
et al showed that rates were similar for patients classified as
low risk but were divergent in patients assessed as moderate
risk, with observed annual event rates of 4.7 and 2.0,
respectively. They also explored the relative importance of the
various risk factors incorporated into the scores and showed
that age >75 was the dominant risk factor in CHADS2 (and
hypertension the least important) and diabetes the most
important factor in CHA2DS2-VASc. Such registry studies are
complemented by data such as in the BAFTA study, which are
not subject to the potential ascertainment bias of registries and
are controlled for use of drug treatments. Furthermore, these
BAFTA data are uniquely focused on the performance of the
riskscoresinthoseover75,notseparatedintheOlesonpaper,
15
the most important population for stroke prevention in atrial
fibrillation.
Wetestedthepredictivepowerofthemainscoringschemesfor
risk of stroke advocated in international guidelines against the
observed rates of stroke and thromboembolic events in people
aged over 75 with chronic atrial fibrillation recruited to the
BAFTA trial. The relevance of this cohort being patients aged
over75,byfarthemostcommongrouptohaveatrialfibrillation,
is that they have been under-represented in previous atrial
fibrillationtrialsand,further,theBAFTAstudypopulationwas
representative of older people in the general population with
atrial fibrillation because of the limited study exclusions.
Methods
We compared the performance of the commonly used stroke
riskstratificationschemesinacontemporarypopulationofolder
people. Seven schemes were applied to a subset of data from
the BAFTA study.
Stroke risk stratification schemes
The schemes evaluated were CHADS2,
16 Framingham,
17 NICE
guidelines,
18 ACC/AHA/ESC (American College of
Cardiology/American Heart Association/European Society of
Cardiology) guidelines,
19 ACCP guidelines,
20 and the more
recently developed CHA2DS2-VASc
21 and Reitbrock modified
CHADS2 scheme.
22 All but the Reitbrock scheme classify
patients into risk categories (low, moderate, high) following
stratification rules (table 1). All seven schemes identify older
age, previous stroke/transient ischaemic attack, and diabetes as
risk factors. All but Reitbrock include hypertension
(Framingham includes systolic blood pressure). Heart failure
or left ventricular dysfunction is included in all schemes except
Framingham and Reitbrock. Other factors considered are sex
(Framingham,Reitbrock,CHA2DS2-VASc),valvedisease(NICE
and ACC/AHA/ESC (mitral stenosis)), and vascular disease
(NICE, CHA2DS2-VASc).
The CHADS2 index is the simplest to construct, with a score
ranging from 0 to 6; two points are given for previous
stroke/transient ischaemic attack and one point for each of
congestive heart failure, hypertension, age 75 and older, and
diabetes. A reported weakness of the original CHADS2 score is
that a person with previous stroke or transient ischaemic attack
and no other risk factors was allocated to the moderate risk
category, despite the medical history suggesting high risk.
23 To
addressthislimitation,therevisedCHADS2index(score0=low
risk; 1=moderate risk; 2-6 high risk) was proposed to replace
theoriginalCHADS2(score0=lowrisk;1-2=moderaterisk;3-6
high risk). More recently Reitbrock et al further modified
CHADS2 into a new scale from 0 to 14, where the original
algorithm was altered by reweighting age, including sex, and
removing heart failure and hypertension.
22 The risk strata cut
offsforthisscale,however,havenotbeenpublishedsoanalysis
Reprints: http://journals.bmj.com/cgi/reprintform Subscribe: http://resources.bmj.com/bmj/subscribers/how-to-subscribe
BMJ 2011;342:d3653 doi: 10.1136/bmj.d3653 Page 2 of 13
RESEARCHof this scheme is performed on the score only. The new
CHA2DS2-VASc score is expressed as a point based scoring
system from 0 to 9, whereby 0=low risk, 1=intermediate, and
≥2 is high risk. The CHA2DS2-VASc score evolved from the
ACC/AHA/ESCandNICEguidelinesandinitiallytestedalarge
cohort of patients from the Euro Heart Survey for atrial
fibrillation.Internationalguidelinesrecommendthatallpatients
assessed as high risk and most patients at moderate risk with
these scores are offered warfarin, unless it is contraindicated or
not tolerated. Recommendations are more varied for patients at
low risk, with some guidelines advocating aspirin and some no
medication.
Investigational cohort
The investigational cohort for this analysis is a subset of
participantsoftheBirminghamAtrialFibrillationTreatmentof
the Aged (BAFTA) trial.
11 In brief, this randomised controlled
trial,undertakeninprimarycare,comparedwarfarinwithaspirin
for strokepreventioninolder people withatrial fibrillation.The
trial recruited 973 patients aged 75 and over from 260 general
practices throughout England and Wales from 2001 to 2004.
Eligible patients were identified from general practice registers
and opportunistic pulse tests during routine general practice
visits. Atrial fibrillation was confirmed by a study
electrocardiogram or by electrocardiography performed in the
previoustwoyearsifthestudyelectrocardiogramshowedsinus
rhythm but there was evidence that the patient had paroxysmal
atrial fibrillation. All potential strokes, systemic emboli, and
transient ischaemic attacks were independently adjudicated.
The study population for these analyses comprised BAFTA
patients not taking warfarin for all or part of the trial period
(n=665); table 2 shows the demographics. For this analysis,
participants contributed person years at risk only for the time
they were not taking warfarin. Sensitivity analyses were
performed on a subset of patients identified as taking aspirin
throughout the trial (n=368).
Statistical methods
Our primary analysis focused on the predictive accuracy of the
different tools in classifying the risk of ischaemic stroke.
Secondary analyses examined the tools’ performance for
predictionofischaemicstroke,systemicembolism,ortransient
ischaemic attack. Event rates (per 100 person years) were
calculated for each risk scheme and stratum, with 95%
confidence intervals estimated with the Poisson exact method.
To assess the validity of the schemes, we used Cox proportion
hazards regression analysis on the time to event data. Hazard
ratios were obtained to measure the increased risk of stroke
across the risk strata. The C statistic was calculated to quantify
the discriminatory ability of each risk scheme, where a value
of 0.5 indicates that the tool performs no better than chance.
Bootstrapping was undertaken to assess the accuracy of the C
statistic. It enables us to calculate a distribution of the C statistic
from which we can calculate the 95% confidence interval. If
the confidence interval overlaps 0.5, then the risk tool’s
predictive ability is no better than chance. The 95% confidence
intervalsforeachCstatisticwereestimatedfromcentiles(2.5th,
97.5th) obtained from bootstrap resampling with 1000
replications.Theseintervalsalsoenablecomparisonstobemade
between risk strata. For comparison across schemes, allowing
forcorrelationbetweenthem,wecalculateddifferencesbetween
the C statistics for each paired comparison from every
bootstrapped sample. The difference between the schemes was
considered significant if the 95% confidence interval of these
bootstrapped differences did not include zero.
The risk tools under consideration have been designed for use
in adults. As BAFTA is a study of people aged 75 and over, we
carried out an additional time to event analysis to confirm
whetherthoseindependentriskfactors,identifiedbythevarious
schemes,areconfirmedinthenewmodelderivedfromanolder
population. Variables considered were age, sex, systolic blood
pressure, history of stoke or transient ischaemic attack, valve
disease, hypertension, diabetes, myocardial infarction, angina,
and heart failure. Trial participants were recruited from many
general practices so we examined potential clustering effect
using a Cox shared frailty model.
24 The proportional hazards
assumptionswerecheckedwithSchoenfeldresiduals.
25Analyses
were performed with SAS version 9.1 and Stata Version 10.
Results
Of the patients randomised to the BAFTA trial, 665 aged 75 or
overwithatrialfibrillationwereidentifiedasnottakingwarfarin
throughoutorforpartofthestudyperiod.Themedianfollow-up
of these patients while they were not taking warfarin was 2.2
years (range 0-5.3 years), the mean age was 81 (SD 4.3), and
55% (367) were men (table 2). The distribution of patients
classified into the three risk categories was similar across the
revised CHADS2, NICE, ACC/AHA/ESC, and ACCP, with
most patients categorised as high risk (65-69%, 430-457), and,
with the exception of ACCP, the remaining were classified as
moderate risk. The original CHADS2 identified the fewest as
high risk (27%, 180). Only Framingham and ACCP classified
somepatientsaslowrisk(17%(112)and3%(19),respectively).
TheCHA2DS2-VAScscoreclassifiedallpatients(givenallwere
aged ≥75) as high risk. Three items required for the calculation
ofACC/AHA/ESC—namely,impairedleftventricularfunction,
mitral stenosis, and prosthetic heart valve—were exclusion
criteria for the BAFTA trial, hence this scheme produced
estimates identical to the revised CHADS2.
During the trial follow-up, 54 patients (8%) had an ischaemic
stroke, four (0.6%) had a systemic embolism, and 13 (2%) had
a transient ischaemic attack. Table 3 shows the number of
observed ischaemic strokes, patient years, and event rates by
each risk stratum for the different schemes. The highest rates
of stroke were in the high risk category, with rates across all
stratification schemes ranging between 4.36 per 100 person
years for NICE to 4.98 per 100 person years for the original
CHADS2.Thesehighriskeventratesweresignificantlydifferent
from the moderate rates for all schemes, except the original
CHADS2 and Framingham. A low rate of 0.76 per 100 person
years was found for the low risk strata of Framingham and 2.38
per 100 person years for low risk as defined by ACCP. The
incremental risk scores of CHADS2, Rietbrock, and
CHA2DS2-VASc failed to show an increase in risk at the upper
rangeofscores(table4).Thefigureshowsthesimilarityofrisk
rates of CHADS2 scores 2 and above.
Table 5 shows the performance characteristics of the different
stratification schemes. With the exception of Framingham and
the original CHADS2, schemes that enabled categorisation of
patients into risk strata showed about a threefold increase in
risk of stroke when patients move between moderate and high
categories of risk. The revised CHADS2 had the highest hazard
ratio, with a significant increase in risk from moderate to high
of 3.29 (95% confidence interval 1.49 to 7.28). The CHADS2
index, Rietbrock modified, and CHA2DS2-VASc scoring
schemes estimating a 17-35% increase in risk per unit change
in score. The predictive accuracy was similar across the seven
schemes, with the C statistic ranging from 0.55 (original
CHADS2)to0.62(RietbrockmodifiedCHADS2),withallexcept
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RESEARCHtheoriginalCHADS2predictingbetterthanchance.Bootstrapped
paired comparisons provided no evidence of significant
differences between the discriminatory ability of the schemes.
Evaluationofthevalidityofthedifferentclassificationschemes
identifying the additional events of systemic embolism and
transient ischaemic attack produced similar results (see tables
B and D in appendix on bmj.com).
Thesensitivityanalysisof368patientstakingaspirinthroughout
the trial follow-up period, with 34 ischaemic strokes occurring
in this population, showed similar risk rates to those observed
across the primary population of all non-warfarin users (see
tables A and C in appendix on bmj.com). The Framingham risk
rate of ischaemic stroke in the moderate group (5.03 per 100
person years) was greater in magnitude than in the high risk
group (3.63 per 100 person years). Comparison of confidence
intervals,however,confirmednosignificantdifferencebetween
these categories. There was a wider range of C statistics from
0.5 (original CHADS2) to 0.62 (Framingham) compared with
the prediction of stroke only, but again there was no evidence
of any significant differences between the schemes.
Table 6 presents the results of the Cox proportional hazards
survival analysis to identify independent risk factors in these
older people with atrial fibrillation. As there was no evidence
of practices having a clustering effect on the outcome, it was
excluded from the further analyses. After adjustment for all
otherfactorsinthemodel,onlyhistoryofdiabetes(hazardratio
2.06, 1.07 to 3.98) and previous stroke or transient ischaemic
attack (2.59, 1.36 to 4.90) were identified as significant risk
factors of ischaemic stroke. A rule with these two factors has a
moderateabilitytopredictstroke(Cstatistic0.60,0.53to0.68).
Discussion
This comprehensive assessment of current risk stratification
schemes in older people with atrial fibrillation, commonly
recommended in international guidelines, has shown that all
schemesstudiedhaveasimilarlimitedabilitytopredicttherisk
of stroke. The significance of these results is threefold: the
prevalence of atrial fibrillation is highest in older people
(approaching 60% of patients with atrial fibrillation in the UK
are over 75), among people with atrial fibrillation, stroke is
more common in the older patients, and, when they do occur,
strokes tend to be more disabling in older people. Previous
studies have systematically under-represented older people,
leaving uncertainty about how to weight age within the current
risk scores. These data therefore provide original estimates of
the utility of existing scores in the most important target
population for prevention of stroke in people with atrial
fibrillation.
All the schemes evaluated worked similarly, with the highest
event rates for stroke occurring in the high risk category. This
was also observed in the composite event rates for systemic
embolism and transient ischaemic attack. The proportion of
patients that are classified as high, moderate, or low risk,
however, varies considerably across the schemes. These
observed differences are reflected in the general inconsistent
use of anticoagulation in the treatment of patients with atrial
fibrillation.ThesimplereclassificationofCHADS2,wherethose
with a score of 2 or more are categorised at high risk, resulted
in the largest hazard ratio. Its ability to discriminate between
the risk groups, with a C statistic of 0.61, however, is similar
to the other schemes. Previous concern with the original
CHADS2 was confirmed by its failure to show a significant
increase in risk between the moderate and high risk strata. Its
Cstatisticisalsolowestinmagnitudeandwasfoundtoperform
no better than chance in the BAFTA data. The moderate ability
of the tools to predict stroke in these older people is therefore
similar to the results seen in previous research across wider age
groups.
9 26
Study limitations
Patients recruited for the BAFTA trial were those for whom
general practitioners were in equipoise over the benefits and
risks of treatment. Therefore, those perceived as at highest risk
might have been less likely to have been recruited. However, a
rangeof“atrisk”olderpeoplewererandomised,includingsome
living in nursing homes (and requiring carer consent), those
previously treated with warfarin, and people with previous
stroke. We were unable to assess some of the risk factors in the
ACC/AHA/ESC scheme because of the lack of available data.
The C statistics and hazard ratios for the point scoring schemes
of CHADS2, Rietbrock, and CHA2DS2-VASc should be read
withcautionasthelownumberofeventspreventedthelinearity
assumption for these scales being adequately tested. Also, all
participants in BAFTA were classified as “high risk” based on
the CHA2DS2-VASc score (that is, ≥2). We cannot account for
any unanticipated influence of previous exposure to drug
treatment on subsequent embolic events, though sensitivity
analysis of those taking aspirin throughout generated similar
results.
Clinical relevance
These data are important as high risk atrial fibrillation patients
shouldbeofferedvitaminKantagonistsinmostcircumstances,
yet vitamin K antagonists are underused for stroke prevention.
The NICE recommendations for atrial fibrillation treatment
estimated that nationally of 355 312 patients with atrial
fibrillationwhoshouldbetakingwarfarin,165946(50%)were
not receiving it.
27 Audits suggest that warfarin continues to be
underused in the UK.
28 29 This pattern of underuse of vitamin K
antagonists recurs internationally, with data from the US
30
showing only about one third of visits of patients for atrial
fibrillation included mentions of vitamin K antagonists, with
no significant change over time, and Spain, where 69% of 1178
patients with atrial fibrillation were not taking anticoagulants,
31
despite 89% patients having strong indications for
anticoagulation. Furthermore, data suggest that use of vitamin
K antagonist declines over time,
32 with one North American
studyshowinga65%useofwarfarinatdiagnosisbutonly44%
taking it at 30 months. Even in “ideal” candidates for a vitamin
K antagonist, the rate of its prescription decreased from 70% at
baseline to 50% at 30 months.
Therearerecogniseddifficultiesinimplementingtheguidelines
for anticoagulant, ranging from reluctance of patients to adopt
currenttreatmentguidelinestodifficultiesinidentifyingpatients
with atrial fibrillation
33—diagnosis of atrial fibrillation in older
patients can be a particular challenge in that older adults might
have no symptoms or might present with such atypical
symptoms as a change in function, mood, or cognition.
Moreover, physicians’ reluctance to use vitamin K antagonists
has repeatedly been shown to be associated with a false
understanding of the benefit to risk ratio, which arises from a
low appreciation of therapeutic benefits and a high concern
regarding haemorrhage.
34 A study in the Netherlands to assess
which clinical determinants influence prescription of coumarin
and aspirin in patients with atrial fibrillation in primary care
foundthatphysicians’decisionsaboutinitiatingantithrombotic
treatmentinatrialfibrillationwerenotevidencebasedandwere
guided only partly by thromboembolic risk stratification but
also by factors insignificant for thromboembolic risk.
35
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RESEARCHEstablishedriskfactorsforfuturethromboembolicevents,such
as hypertension and diabetes mellitus, did not lead to higher
prescription rates of coumarin compared with aspirin, but, in
contrast, several factors not associated with thromboembolic
events, such as chronic (versus paroxysmal) atrial fibrillation
(adjusted odds ratio 3.7, 1.7 to 8.2) and longstanding (versus
recent) diagnosis (2.2, 1.1 to 4.5), were associated with higher
coumarin prescription.
Importance in older people
TheunderprescribingofvitaminKantagonistsinolderpatients
is a particular issue.
14 Age is itself a recognised risk factor in
both the CHADS2 and NICE schemes that should be linked to
higher risk scores and therefore increased probability of being
prescribedanticoagulants.VitaminKantagonists,however,are
even less likely to be optimally prescribed to this group,
probablycompoundedbymanyguidelinesassessingageasboth
a risk factor for stroke and a caution for risk of bleeding with
anticoagulation. Unsurprisingly therefore, older people are the
least likely to be receiving preventive treatment, despite being
the most at risk: among patients with atrial fibrillation admitted
to hospital in Ireland, those aged 75 and older were more likely
to be receiving suboptimal oral antithrombotic treatment
compared with younger patients.
36 In Canada, 46% of atrial
fibrillationpatientsdeemedappropriatecandidatesforwarfarin
were not prescribed it, and age was a particularly important
factor. Multivariable analysis found that increasing age was
associated with a reduced odds of use of a vitamin K antagonist
(odds ratio 0.7, 0.5 to 0.9); 75% of those under 75 considered
suitable by the study’s authors were prescribed vitamin K
antagonists compared with only 33% of those over 85.
37 Of 111
patients with atrial fibrillation in west Birmingham who were
not receiving an anticoagulant (n=71), less than 17% had
contraindications, and patients treated with warfarin were
significantly younger than those who were not prescribed it.
38
AsimilarpatternhasbeenidentifiedinIceland,
39Sweden,
40and
the US.
41
Better prevention of stroke in older patients with atrial
fibrillationisthereforeapriority.Importantly,theBAFTAtrial
11
and subsequent individual patient data meta-analysis
12 have
shown that the risk of bleeding with warfarin in older patients
is no greater than with aspirin. Indeed the meta-analysis shows
that whereas the benefits and risks of warfarin remain constant
acrossallagebands,aspirinbecomesprogressivelylesseffective
and the risk of bleeding increases with advancing age, with its
effectiveness in preventing stroke seeming to cease beyond the
age of 70.
12 Furthermore, the options for anticoagulation
treatment are being expanded beyond warfarin. A new direct
thrombin inhibitor, dagibatran, recently gained European
approval for marketing in atrial fibrillation
thromboprophylaxis,
42 as did two factor Xa inhibitors:
rivaroxaban recently showed equivalence to warfarin in
prevention of atrial fibrillation stroke
43 and apixiban showed a
greater than 50% risk reduction in thromboembolic events
compared with aspirin in atrial fibrillation patients who could
nottoleratewarfarin.
44Therefore,evenifpatientsandphysicians
remain reluctant to prescribe warfarin, accurate identification
of those at high thromboembolic risk remains a priority as
effectivemanagementalternativestowarfarinoptions,thatdon’t
require monitoring, become available. Offering such patients
aspirin is an inappropriate option.
None of the stroke risk scores performed particularly well in
these older people, with the best performance of the revised
CHADS2 and CHA2DS2-VASc managing only a C statistic
around 0.60. This compares with the C statistics of >0.70
observed for the various commonly used 10 year estimates for
cardiovascular disease. Based on these data, a more pragmatic
solution to better stroke prevention in atrial fibrillation in older
people might be to recommend that all patients over 75 are
considered for anticoagulation (as suggested in the 2010
European Society of Cardiology guidelines) without the need
for a risk score and to reserve the use of risk scores for those
under 75.
Conclusions
All the schemes studied had a similar limited ability to predict
the risk of stroke. With the exception of the original CHADS2,
their performance is better than chance, though further
development is required to improve the accuracy of the tools in
olderpeopleanditmightbebettertopragmaticallyrecommend
thatcliniciansclassifyallpatientsover75ashighriskandoffer
oral anticoagulation for these patients until better tools are
available.
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RESEARCHTables
Table 1| Stroke risk stratification schemes for patients with atrial fibrillation
High risk Moderate risk Low risk Risk scheme
Score 3-6 (original); 2-6 (revised) Score 1-2 (original); 1 (revised) Score 0 (original); 0 (revised) CHADS2 (2001)
16*
Score 14-31 Score 8-13 Score 0-7 Framingham (2003)
17†
Previous ischaemic stroke, transient ischaemic
attack, or systemic embolic event; age ≥75 with
hypertension, diabetes, or vascular disease; clinical
evidence of valve disease or heart failure; impaired
left ventricular function on echocardiography
Age ≥65 with no high risk factors; age <75
with hypertension, diabetes, or vascular
disease
Age <65 with no history of
embolism, hypertension,
diabetes, or other clinical risk
factors
NICE guidelines (2006)
18
Previous stroke, transient ischaemic attack,
systemic embolism; mitral stenosis; prosthetic heart
valve; two or more of: age ≥75, hypertension,
diabetes, heart failure, or impaired left ventricular
function
Patient with only one risk factor: age ≥75;
hypertension, diabetes, heart failure, or
impaired left ventricular function
No risk factors ACC/AHA/ESC guidelines
(2006)
19
Previous stroke, transient ischaemic attack,
systemic embolism; two or more of: age >75,
hypertension, diabetes, or impaired left ventricular
function with or without heart failure
Patients with only one risk factor: age >75,
hypertension, diabetes, or impaired left
ventricular function with or without heart
failure
Age ≤75 with no risk factors ACCP guidelines (2008)
20
NA NA NA Rietbrock modified (2008)
22‡
Score 2-9 Score 1 Score 0 CHA2DS2-VASc (2009)
21§
NA=not available.
*Scoring system based on previous stroke or transient ischaemic attack (2 points), age ≥75 (1 point), hypertension (1 point), diabetes (1 point), congestive heart
failure (1 point).
†Scoring system based on age (max 10 points), female (6 points), raised systolic blood pressure (max 4 points), diabetes (5 points), previous stroke or transient
ischaemic attack (6 points).
‡Scoring system based on age (max 6 points), female (1 point), diabetes (1 point), history of stroke/transient ischaemic attack (6 points).
§Scoring system based on congestive heart failure (1 point), hypertension (1 point), age ≥75 (2 points), diabetes (1 point), stroke/transient ischaemic
attack/thromboembolism (2 points), vascular disease (1 point), age 65-74 (1 point), female (1 point).
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RESEARCHTable 2| Characteristics of participants in Birmingham Atrial Fibrillation in the Aged (BAFTA) trial who were not taking warfarin
No (%) Risk factor
Age (years):
253 (38) 75-79
266 (40) 80-84
146 (22) ≥85
367 (55) Men
Systolic BP (mm Hg):
83 (13) <120
208 (31) 120-139
239 (36) 140-159
124 (19) 160-179
11 (2) ≥180
91 (14) Diabetes
355 (53) Hypertension
78 (12) Previous stroke or transient ischaemic attack
42 (6) Valve disease
74 (11) Myocardial infarction
108 (16) Angina
121 (18) Heart failure
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RESEARCHTable 3| Distribution and risk of ischaemic stroke in patients aged ≥75 with atrial fibrillation who were not taking warfarin, by classification
of risk and scheme*
Risk/100 person years (95% CI†) Events/person years Distribution (%) Risk
CHADS2original
— — 0 Low risk
3.05 (2.12 to 4.27) 34/1113 73 Moderate risk
4.98 (3.07 to 7.58) 20/402 27 High risk
CHADS2 revised
— — 0 Low risk
1.39 (0.56 to 2.86) 7/505 31 Moderate risk
4.65 (3.42 to 6.19) 47/1010 69 High risk
Framingham
0.76 (0.09 to 2.72) 2/263 17 Low risk
3.84 (2.48 to 5.66) 24/625 42 Moderate risk
4.47 (2.97 to 6.39) 28/627 41 High risk
NICE
— — 0 Low risk
1.45 (0.53 to 3.12) 6/415 25 Moderate risk
4.36 (3.23 to 5.74) 48/1100 75 High risk
ACC/AHA/ESC‡
— — 0 Low risk
1.39 (0.56 to 2.86) 7/505 31 Moderate risk
4.65 (3.42 to 6.19) 47/1010 69 High risk
ACCP
2.38 (0.06 to 13.27) 1/42 3 Low risk
1.73 (0.79 to 3.29) 9/519 32 Moderate risk
4.61 (3.35 to 6.19) 44/954 65 High risk
*With CHA2DS2-VASc, all patients would be classified as “high risk.”
†Calculated with Poisson exact method.
‡Equal to CHADS2 revised because of unavailability of risk factors (left ventricular function, mitral stenosis, and prosthetic heart valve) in BAFTA data.
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RESEARCHTable 4| Risk of ischaemic stroke in patients aged ≥75 with atrial fibrillation who were not taking warfarin, by incremental score in risk
schemes
Risk/100 person years (95% CI) Events/person years Score
CHADS2index
— — 0
1.39 (0.56 to 2.86) 7/505 1
4.45 (2.95 to 6.41) 27/607 2
5.24 (2.82 to 8.80) 13/248 3
3.48 (0.96 to 8.67) 4/115 4
8.57 (1.80 to 23.06) 3/36 5
0 (0 to 84.19)* 0/2 6
CHA2DS2-VASc
— — 0
— — 1
2.11 (0.77 to 4.60) 6/284 2
1.89 (0.91 to 3.48) 10/529 3
6.69 (4.28 to 9.95) 24/359 4
4.06 (1.75 to 8.01) 8/197 5
5.45 (2.00 to 11.87) 6/110 6
0 (0 to 11.90)* 0/ 31 7
0 (0 to 73.78)* 0/5 8
Rietbrock modified CHADS2
— — 0
— — 1
— — 2
— — 3
1.16 (0.24 to 3.40) 3/258 4
2.84 (1.56 to 4.77) 14/492 5
3.32 (1.77 to 5.69) 13/391 6
4.23 (1.83 to 8.34) 8/189 7
25.0 (5.16 to 73.06) 3/12 8
— 0 9
14.81 (4.04 to 37.93) 4/27 10
7.58 (2.46 to 17.68) 5/66 11
6.52 (1.34 to 19.06) 3/46 12
2.94 (0.07 to 16.39) 1/34 13
*One sided 97.5% confidence interval.
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RESEARCHTable 5| Performance of risk stratification schemes to predict ischaemic stroke in patients aged ≥75 with atrial fibrillation who were not
taking warfarin
P value Hazard ratio (95% CI) C statistic* Risk scheme
Stratum
0.09 1.61 (0.93 to 2.80) 0.55 (0.49 to 0.61) CHADS2original
0.003 3.29 (1.49 to 7.28) 0.61 (0.57 to 0.66) CHADS2revised
Framingham:
0.03 4.99 (1.18 to 21.10) 0.59 (0.55 to 0.65) Moderate v low
0.56 1.17 (0.68 to 2.03) High v moderate
0.01 2.93 (1.25 to 6.68) 0.59 (0.54 to 0.63) NICE
0.003 3.29 (1.49 to 7.28) 0.61 (0.57 to 0.66) ACC/AHA/ESC†
ACCP:
0.78 0.75 (0.09 to 5.89) 0.60 (0.54 to 0.65) Moderate v low
0.009 2.61 (1.27 to 5.35) High v moderate
Scores
0.01 1.35 (1.07 to 1.70)‡ 0.61 (0.54 to 0.68) CHADS2 index
0.001 1.17 (1.06 to 1.29)‡ 0.62 (0.59 to 0.68) Rietbrock modified
0.06 1.21 (0.99 to 1.47)‡ 0.60 (0.55 to 0.68) CHA2DS2-VASc
*Assesses discrimination where 0.5 is non-informative test.
†Equal to CHADS2 revised because of unavailability of risk factors left ventricular function, mitral stenosis, and prosthetic heart valve in BAFTA data.
‡Per unit increase in score.
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RESEARCHTable 6| Cox proportional hazards model estimating risk of ischaemic stroke in people aged ≥75 with atrial fibrillation who were not taking
warfarin
P value Hazard ratio Variable
0.14 1.26 (0.93 to 1.72) Age (per 5 years)
0.96 0.99 (0.57 to 1.70) Sex
0.86 1.01 (0.94 to 1.08) Systolic blood pressure (per 5 mm Hg)
0.74 1.10 (0.62 to 1.95) Hypertension
0.03 2.06 (1.07 to 3.98) Diabetes
0.53 0.78 (0.36 to 1.68) Heart failure
0.22 0.52 (0.18 to 1.50) Myocardial infarction
0.79 1.12 (0.30 to 2.44) Angina
0.95 0.96 (0.58 to 3.13) Valve disease
0.003 2.59 (1.36 to 4.90) Stroke/TIA
TIA=transient ischaemic attack.
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RESEARCHFigure
Risk of ischaemic stroke (point estimates with 95% confidence interval) by individual CHADS2 score
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